1. Home
  2. CYBN vs CCCC Comparison

CYBN vs CCCC Comparison

Compare CYBN & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYBN
  • CCCC
  • Stock Information
  • Founded
  • CYBN 2019
  • CCCC 2015
  • Country
  • CYBN Canada
  • CCCC United States
  • Employees
  • CYBN N/A
  • CCCC N/A
  • Industry
  • CYBN Pharmaceuticals and Biotechnology
  • CCCC Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYBN Health Care
  • CCCC Health Care
  • Exchange
  • CYBN Nasdaq
  • CCCC Nasdaq
  • Market Cap
  • CYBN 176.0M
  • CCCC 175.1M
  • IPO Year
  • CYBN N/A
  • CCCC 2020
  • Fundamental
  • Price
  • CYBN $7.11
  • CCCC $2.61
  • Analyst Decision
  • CYBN Strong Buy
  • CCCC Buy
  • Analyst Count
  • CYBN 3
  • CCCC 2
  • Target Price
  • CYBN $85.00
  • CCCC $8.00
  • AVG Volume (30 Days)
  • CYBN 351.0K
  • CCCC 1.6M
  • Earning Date
  • CYBN 08-13-2025
  • CCCC 08-07-2025
  • Dividend Yield
  • CYBN N/A
  • CCCC N/A
  • EPS Growth
  • CYBN N/A
  • CCCC N/A
  • EPS
  • CYBN N/A
  • CCCC N/A
  • Revenue
  • CYBN N/A
  • CCCC $34,240,000.00
  • Revenue This Year
  • CYBN N/A
  • CCCC N/A
  • Revenue Next Year
  • CYBN N/A
  • CCCC N/A
  • P/E Ratio
  • CYBN N/A
  • CCCC N/A
  • Revenue Growth
  • CYBN N/A
  • CCCC 16.55
  • 52 Week Low
  • CYBN $4.81
  • CCCC $1.09
  • 52 Week High
  • CYBN $13.88
  • CCCC $7.22
  • Technical
  • Relative Strength Index (RSI)
  • CYBN 45.43
  • CCCC 59.15
  • Support Level
  • CYBN $6.36
  • CCCC $2.47
  • Resistance Level
  • CYBN $7.75
  • CCCC $3.07
  • Average True Range (ATR)
  • CYBN 0.34
  • CCCC 0.29
  • MACD
  • CYBN -0.04
  • CCCC 0.01
  • Stochastic Oscillator
  • CYBN 51.95
  • CCCC 59.19

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: